BayPAT’s Licensee Dualyx NV raises 40€ million to progress Treg therapies for autoimmune diseases into the clinic
25.05.2023
Dualyx NV, was founded three years ago by CSO Luc Van Rompaey, in a collaborative model with Julius Maximilians University (JMU), Argenx, VIB, Ghent University and KU Leuven. The Ghent-based biotech company is developing next generation immune modulators for difficult to treat autoimmune diseases.
The lead program DT-001, which targets the highly attractive TNF receptor 2 (TNFR2), widely regarded as a master control switch in immune modulation, is subject to an exclusive license agreement concluded in 2021 between BayPAT and Dualyx NV and is based on research originating from Julius-Maximilians-Universität Würzburg (JMU). Through state-of-the-art antibody engineering, Dualyx NV has developed an agonist to the receptor which shows highly selective activation of regulatory T cells (Tregs).
To date, promising results have been observed from pre-clinical research with DT-001 and investigational new drug (IND)-enabling studies have begun. As CEO Wouter Verhoeven points out, DT-001 holds promise to be a game-changing treatment option for a broad range of autoimmune diseases. The funds will be used to progress Dualyx’s DT-001 program into its early clinical proof-of-concept phase. „This is great news, we are very happy to witness our licensee’s successful Series A funding, propelling the progress of new concepts for autoimmune therapy.“ added Dr. Robert Phelps, BayPAT’s Chief Executive Officer The company has a pipeline of additional Treg focused programs in early-stage development.
Dualyx is backed by a group of well-respected investors including: Fountain Healthcare Partners, Forbion, Andera Partners, V-Bio Ventures, BGV, PMV, VIB, HTGF and GFF.
About BayPAT
Bayerische Patentallianz GmbH (BayPAT) was founded in 2007 by the Universität Bayern e.V. and the Hochschule Bayern - the Bavarian Universities of Applied Sciences - e.V. as the central patent and marketing agency to foster technology transfer of Bavarian Universities, University Hospitals and Universities of Applied Sciences and is responsible for 28 research institutes. Under the umbrella of the Bavarian Research and Innovation Agency (BayFIA), BayPAT (www.baypat.de) is a full-service technology management provider offering services in the areas of technology transfer, IP management and IP commercialisation. Key clients are the Bavarian Universities, University Hospitals and Universities of Applied Sciences and its over 25,000 associated scientists, as well as non-university research institutes, industry and independent inventors worldwide. BayPAT’s main focus in assessing and exploiting IP are the areas of therapeutics, diagnostics, biotechnology, chemistry, medical technology, physics, automotive industry, energy and environment engineering, information and communication technology as well as mechanical engineering.
Ihr Kontakt:
